Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

This study is ongoing, but not recruiting participants.

Study NCT00086775 Information provided by National Cancer Institute (NCI)

First Received: July 8, 2004 Last Updated: February 6, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Leukemia

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

alemtuzumab
rituximab
fludarabine phosphate

Additional drug interventions recognized in this trial

More general drug interventions related to this trial

Sponsors listed in this trial

Bayer